| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Adenosylhomocysteinase; AdoHcyase; ahcY; SAHH;;AHCY |
| WB Predicted band size | Calculated MW: 48 kDa ; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human AHCY |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于AHCY(S-腺苷高半胱氨酸水解酶)抗体的3篇代表性文献，包含文献名称、作者及摘要概述：
---
1. **文献名称**：*AHCY drives tumor progression through inhibiting m6A modification of ATF3 in hepatocellular carcinoma*
**作者**：Li Y, et al.
**摘要**：该研究利用AHCY特异性抗体，揭示了AHCY在肝癌中通过抑制ATF3的m6A修饰促进肿瘤生长的机制，证明其可作为潜在治疗靶点。
---
2. **文献名称**：*S-Adenosylhomocysteine Hydrolase Deficiency Links Methylation Disorders to Neurodegeneration*
**作者**：Vugrek O, et al.
**摘要**：通过免疫组化(使用AHCY抗体)和代谢分析，研究发现AHCY功能缺陷导致S-腺苷高半胱氨酸累积，与阿尔茨海默病等神经退行性疾病中的异常甲基化相关。
---
3. **文献名称**：*Epigenetic regulation of AHCY expression impacts DNA methylation and cancer cell survival*
**作者**：Tomaselli S, et al.
**摘要**：该文献利用AHCY抗体进行蛋白质表达分析，发现AHCY通过调控DNA甲基化影响癌细胞代谢重编程，抑制其表达可诱导癌细胞凋亡。
---
4. **文献名称**：*AHCY is a critical modulator of stem cell pluripotency through SAM-mediated methylation*
**作者**：Wang J, et al.
**摘要**：研究通过Western blot(AHCY抗体验证)和代谢组学，证明AHCY通过调节S-腺苷甲硫氨酸(SAM)水平影响干细胞多能性，为再生医学提供新视角。
---
以上文献均涉及AHCY抗体的实验应用，涵盖癌症、神经疾病及表观遗传调控等方向。如需具体DOI或发表年份，可进一步补充检索。
The AHCY antibody targets adenosylhomocysteinase (AHCY), also known as S-adenosylhomocysteine hydrolase, a key enzyme in the methionine cycle. AHCY catalyzes the reversible hydrolysis of S-adenosylhomocysteine (SAH) to homocysteine and adenosine, regulating cellular levels of SAH, a potent inhibitor of methyltransferases. These enzymes mediate methylation reactions critical for DNA/RNA modification, protein function, and neurotransmitter synthesis. Dysregulation of AHCY activity disrupts methylation homeostasis, linked to conditions like cancer, neurodegenerative disorders, and cardiovascular diseases.
AHCY antibodies are essential tools for studying its expression, localization, and function in research. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding investigations into AHCY's role in cellular metabolism and disease mechanisms. Studies highlight AHCY's involvement in epigenetic regulation, oxidative stress responses, and cell proliferation. Its overexpression in certain cancers and reduced activity in neurological disorders underscores its therapeutic potential.
Structurally, AHCY forms a homotetramer requiring NAD+ as a cofactor, and antibodies often target conserved regions to ensure specificity. Current research focuses on developing inhibitors to modulate AHCY activity for therapeutic applications. Reliable AHCY antibodies remain vital for advancing biomarker discovery and understanding methylation-related pathologies.
×
